All articles tagged with #hims and hers
Novo Nordisk and Hims & Hers Health have ended their patent lawsuit and launched a collaboration, with Wegovy and Ozempic set to move onto the Hims platform as part of a three-part agreement.
Hims & Hers Health stock jumped about 40% after Novo Nordisk announced it would distribute weight-loss medications on the Hims & Hers platform, signaling a potential major partnership and upside for the telehealth company.
Barron’s reports that Hims & Hers Health and Novo Nordisk resolved their clash over GLP-1 drugs, with Novo agreeing to sell Ozempic and Wegovy on Hims’ online pharmacy. Hims stock rose about 38% on the news, while Novo lagged modestly higher; the settlement ends a patent-infringement lawsuit and requires Hims to stop advertising compounded GLP-1 products, though existing patients can transition to FDA-approved options. The deal comes amid FDA scrutiny of compounded GLP-1s and follows years of regulatory and competitive tension between the companies.
Hims & Hers Health announced a strategic shift in its US weight‑loss business, partnering with Novo Nordisk to broaden access to FDA‑approved GLP‑1 therapies on its platform, while phasing out most compounded GLP‑1 offerings (with access preserved only where clinically necessary). The plan includes adding Novo Nordisk products like Ozempic and Wegovy, aligning US and global models, and educating customers to transition to FDA‑approved treatments, aiming to create a large global consumer health platform for affordable medications. The move follows a rapidly evolving GLP‑1 landscape, and Novo Nordisk’s lawsuit against Hims & Hers was dismissed without prejudice.
Novo Nordisk has filed a US lawsuit to block Hims & Hers from selling weight‑loss pills and injections it says are unapproved and infringe its patents, arguing safety concerns over compounded versions. The move comes as the FDA tightens rules on compounding, and amid broader pressure from expiring patents on Wegovy/Ozempic; Hims & Hers’ stock fell while Novo Nordisk edged higher following the filing.
Novo Nordisk filed a lawsuit seeking a permanent ban and damages against Hims & Hers for allegedly selling compounded, patent-infringing versions of Wegovy (semaglutide); Hims paused its obesity-pill copycat after regulatory scrutiny as FDA actions loom, underscoring a broader crackdown on compounded GLP-1 drugs used by as many as 1.5 million Americans amid intense obesity-drug competition.
Hims & Hers has canceled its plan to develop a Wegovy‑style weight‑loss medication, shelving a project to mimic Novo Nordisk’s semaglutide as the company reassesses its drug‑development strategy in the competitive obesity market.
Hims & Hers will stop selling a cheaper, compounded version of Novo Nordisk’s obesity pill Wegovy after health officials called for an investigation into possible federal-law violations; the platform had offered a $49/month compounded version, while Novo Nordisk’s Wegovy costs $149–$299/month, as FDA and HHS/DOJ actions move to curb unapproved compounded GLP-1 drugs.
Novo Nordisk said it will take legal and regulatory action against telehealth provider Hims & Hers after it unveiled a cheaper copycat Wegovy. Hims plans an oral semaglutide pill priced at $49 for the first month and $99 thereafter under a 5-month plan, triggering about 7% declines in Novo Nordisk and Eli Lilly shares; Novo argues the product is illegal mass compounding that risks patient safety, while Hims says its copy uses a different formulation. Wegovy’s SNAC absorption technology is a key point of contrast, and Lilly is preparing its own oral GLP-1, orforglipron, pending FDA approval.
Novo Nordisk says Hims & Hers’ new $49/month, compounded semaglutide version of Wegovy is illegal mass compounding and unsafe, pledging legal action; the FDA has warned against copycat GLP‑1 drugs. The move intensifies price competition in obesity drugs, with Novo forecasting up to a 13% drop in net sales and shares for Novo Nordisk and Lilly slipping.
The FDA has begun cracking down on telehealth companies like Hims & Hers for promoting unapproved and misleading versions of prescription drugs, including weight loss medications, as part of a broader effort to ensure truthful pharmaceutical advertising. The agency sent over 100 cease and desist letters to companies making false claims, highlighting concerns over online drug promotion and advertising practices that may mislead consumers about drug safety and efficacy.
FDA Commissioner Martin Makary criticized Hims & Hers' Super Bowl ad for violating federal law by promoting weight-loss drugs without discussing potential side effects, highlighting concerns over misleading direct-to-consumer pharmaceutical advertising and a decline in FDA enforcement actions.
Hims & Hers Health stock declined while GoodRx shares rose following a deal with Novo Nordisk, reflecting differing market reactions to recent corporate developments.
Hims & Hers, a telehealth company known for weight-loss drugs, experienced a volatile quarter with a significant stock decline due to sales disappointments and market uncertainties, especially in its weight-loss and sexual health segments, raising questions about its long-term growth prospects.
Stock futures rose as markets gained optimism for a September rate cut. Palantir surged 5.3% after strong Q2 earnings and raised full-year guidance, while Vertex fell 16% due to a failed drug trial. Hims & Hers dropped 13% amid lower-than-expected profits, and other companies like DuPont and Axon reported mixed results. BP and AMD showed positive movements, with BP exceeding profit expectations and AMD preparing to report earnings. Several other companies are set to release earnings today.